Entero Historical Financial Ratios
| ENTO Stock | 0.45 0.01 2.17% |
Entero Therapeutics, is recently reporting on over 75 different financial statement accounts. To analyze all of these accounts together requires a lot of time and effort. However, using these accounts to derive some meaningful and actionable indicators such as PTB Ratio of 0.34 or Days Sales Outstanding of 0.0 will help investors to properly organize and evaluate Entero Therapeutics, financial condition quickly.
Entero |
About Entero Financial Ratios Analysis
Entero Therapeutics,Financial ratios are relationships based on a company's financial information. They can serve as useful tools to evaluate Entero Therapeutics, investment potential. Financial ratio analysis can also be defined as the process of presenting financial ratios, which are mathematical indicators calculated by comparing key financial information appearing on Entero financial statements. Financial ratios are useful tools that help investors analyze and compare relationships between different pieces of financial information across Entero Therapeutics, history.
Entero Therapeutics, Financial Ratios Chart
Add Fundamental
Average Payables
The average amount owed to suppliers and creditors over a specific period, reflecting the company's payment cycle and credit terms with suppliers.Payables Turnover
A liquidity ratio that shows how quickly a company pays off its suppliers by dividing total purchases by average accounts payable.Most ratios from Entero Therapeutics,'s fundamentals are interrelated and interconnected. However, analyzing fundamentals ratios one by one will only give a small insight into Entero Therapeutics, current financial condition. On the other hand, looking into the entire matrix of fundamentals ratios, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Entero Therapeutics,. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. To learn how to invest in Entero Stock, please use our How to Invest in Entero Therapeutics, guide.At this time, Entero Therapeutics,'s EV To Free Cash Flow is very stable compared to the past year. As of the 28th of November 2024, Intangibles To Total Assets is likely to grow to 0.35, while PTB Ratio is likely to drop 0.34.
Entero Therapeutics, fundamentals Correlations
Click cells to compare fundamentals
Entero Therapeutics, Account Relationship Matchups
High Positive Relationship
High Negative Relationship
Entero Therapeutics, fundamentals Accounts
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Ptb Ratio | 5.1K | (10.45) | (1.65) | 1.61 | 0.36 | 0.34 | |
| Book Value Per Share | 8.65 | (3.9K) | (3.7K) | 76.36 | 10.71 | 10.18 | |
| Free Cash Flow Yield | (0.001635) | (0.41) | (3.3) | (5.07) | (10.02) | (9.52) | |
| Operating Cash Flow Per Share | (26.28) | (16.6K) | (15.2K) | (622.19) | (36.8) | (38.64) | |
| Capex To Depreciation | 37.95 | 0.007371 | 19.03 | 17.08 | 15.37 | 16.14 | |
| Pb Ratio | 5.1K | (10.45) | (1.65) | 1.61 | 0.36 | 0.34 | |
| Free Cash Flow Per Share | (71.42) | (16.6K) | (20.0K) | (622.19) | (38.29) | (40.2) | |
| Roic | (0.009662) | 18.51 | 11.95 | (3.82) | (3.74) | (3.55) | |
| Net Income Per Share | (28.4K) | (48.3K) | (27.5K) | (407.37) | (46.96) | (49.31) | |
| Payables Turnover | 0.44 | 0.37 | 0.2 | 0.15 | 0.0528 | 0.0502 | |
| Cash Per Share | 0.33 | 9.0K | 3.9K | 37.95 | 11.04 | 10.48 | |
| Pocfratio | (1.7K) | (2.46) | (0.4) | (0.2) | (0.1) | (0.11) | |
| Capex To Operating Cash Flow | (1.72) | (3.71E-4) | (0.32) | (0.0404) | (0.0465) | (0.0488) | |
| Pfcf Ratio | (611.64) | (2.46) | (0.3) | (0.2) | (0.0998) | (0.1) | |
| Days Payables Outstanding | 828.25 | 996.04 | 1.8K | 2.5K | 6.9K | 7.3K | |
| Roe | (3.3K) | 12.37 | 7.48 | (5.34) | (4.38) | (4.6) | |
| Ev To Operating Cash Flow | (1.64) | (1.7K) | (1.97) | (0.18) | 0.13 | 0.14 | |
| Pe Ratio | (1.54) | (0.84) | (0.22) | (0.3) | (0.0813) | (0.0854) | |
| Return On Tangible Assets | (4.2K) | (4.09) | (5.93) | (3.9) | (3.04) | (3.19) | |
| Ev To Free Cash Flow | (611.67) | (1.97) | (0.13) | (0.18) | 0.12 | 0.13 | |
| Earnings Yield | (0.65) | (1.18) | (4.54) | (3.32) | (12.29) | (11.68) | |
| Intangibles To Total Assets | 0.59 | 0.38 | 0.16 | 0.31 | 0.24 | 0.35 | |
| Net Debt To E B I T D A | (9.8E-5) | 0.21 | 0.12 | 0.033 | 0.18 | 0.19 | |
| Current Ratio | 0.8 | 0.51 | 0.77 | 1.37 | 1.58 | 1.66 | |
| Tangible Book Value Per Share | (1.27) | (11.2K) | (4.6K) | 29.46 | 5.7 | 5.42 | |
| Graham Number | 2.4K | 65.1K | 47.8K | 836.59 | 106.39 | 101.07 | |
| Shareholders Equity Per Share | 8.65 | (3.9K) | (3.7K) | 76.36 | 10.71 | 10.18 | |
| Debt To Equity | 329.48 | (0.21) | (0.082) | 0.22 | 0.17 | 0.18 | |
| Capex Per Share | 45.13 | 6.15 | 4.9K | 1.49 | 1.34 | 1.27 | |
| Graham Net Net | 1.2K | (12.5K) | (5.3K) | (8.01) | 1.28 | 1.35 | |
| Interest Debt Per Share | 2.8K | 9.4K | 307.02 | 17.25 | 1.89 | 1.79 |
Pair Trading with Entero Therapeutics,
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Entero Therapeutics, position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Entero Therapeutics, will appreciate offsetting losses from the drop in the long position's value.Moving against Entero Stock
| 0.6 | FDMT | 4D Molecular Therapeutics | PairCorr |
| 0.59 | MRK | Merck Company Fiscal Year End 6th of February 2025 | PairCorr |
| 0.48 | NKTX | Nkarta Inc Buyout Trend | PairCorr |
| 0.45 | RGNX | Regenxbio | PairCorr |
| 0.33 | PEPG | PepGen | PairCorr |
The ability to find closely correlated positions to Entero Therapeutics, could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Entero Therapeutics, when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Entero Therapeutics, - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Entero Therapeutics, to buy it.
The correlation of Entero Therapeutics, is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Entero Therapeutics, moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Entero Therapeutics, moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Entero Therapeutics, can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Entero Therapeutics,. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. To learn how to invest in Entero Stock, please use our How to Invest in Entero Therapeutics, guide.You can also try the ETF Categories module to list of ETF categories grouped based on various criteria, such as the investment strategy or type of investments.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Entero Therapeutics,. If investors know Entero will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Entero Therapeutics, listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (11.04) | Return On Assets (0.27) | Return On Equity (0.15) |
The market value of Entero Therapeutics, is measured differently than its book value, which is the value of Entero that is recorded on the company's balance sheet. Investors also form their own opinion of Entero Therapeutics,'s value that differs from its market value or its book value, called intrinsic value, which is Entero Therapeutics,'s true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Entero Therapeutics,'s market value can be influenced by many factors that don't directly affect Entero Therapeutics,'s underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Entero Therapeutics,'s value and its price as these two are different measures arrived at by different means. Investors typically determine if Entero Therapeutics, is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Entero Therapeutics,'s price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.